Share-based Payment Arrangement, Expense in USD of Sarepta Therapeutics, Inc. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Sarepta Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from 2010 to Q3 2025.
  • Sarepta Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $14,900,000, a 66% decline year-over-year.
  • Sarepta Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $182,514,000, a 22% decline from 2022.
  • Sarepta Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $233,018,000, a 105% increase from 2021.
  • Sarepta Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $113,943,000, a 5.4% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Sarepta Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $14,900,000 -$28,600,000 -66% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $37,000,000 -$13,500,000 -27% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $41,400,000 +$700,000 +1.7% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q3 2024 $180,414,000 $43,500,000 -$4,600,000 -9.6% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $185,014,000 $50,500,000 +$3,100,000 +6.5% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $181,914,000 $40,700,000 -$600,000 -1.5% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $182,514,000 $45,714,000 -$4,796,000 -9.5% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q3 2023 $187,310,000 $48,100,000 -$2,318,000 -4.6% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $189,628,000 $47,400,000 -$55,492,000 -54% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $245,120,000 $41,300,000 +$12,102,000 +41% 01 Jan 2023 31 Mar 2023 10-Q 01 May 2024 2024 Q1
Q4 2022 $233,018,000 $50,510,000 +$20,728,000 +70% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $212,290,000 $50,418,000 +$23,734,000 +89% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $188,556,000 $102,892,000 +$73,923,000 +255% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $114,633,000 $29,198,000 +$690,000 +2.4% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $113,943,000 $29,782,000 +$255,000 +0.86% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
Q3 2021 $113,688,000 $26,684,000 -$219,000 -0.81% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $113,907,000 $28,969,000 +$1,353,000 +4.9% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 $112,554,000 $28,508,000 +$4,484,000 +19% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $108,070,000 $29,527,000 +$7,463,000 +34% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $100,607,000 $26,903,000 +$6,266,000 +30% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $94,341,000 $27,616,000 +$7,854,000 +40% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $86,487,000 $24,024,000 +$7,885,000 +49% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $78,602,000 $22,064,000 +$9,226,000 +72% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $69,376,000 $20,637,000 +$9,153,000 +80% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $60,223,000 $19,762,000 +$4,483,000 +29% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $55,740,000 $16,139,000 +$5,613,000 +53% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $50,127,000 $12,838,000 +$5,472,000 +74% 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
Q3 2018 $44,655,000 $11,484,000 +$4,562,000 +66% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $40,093,000 $15,279,000 +$4,814,000 +46% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $35,279,000 $10,526,000 +$4,814,000 +84% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $30,465,000 $7,366,000 +$497,000 +7.2% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $29,968,000 $6,922,000 -$2,651,000 -28% 01 Jul 2017 30 Sep 2017 10-Q 31 Oct 2018 2018 Q3
Q2 2017 $32,619,000 $10,465,000 +$3,635,000 +53% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $28,984,000 $5,712,000 -$978,000 -15% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018 2018 Q1
Q4 2016 $29,962,000 $6,869,000 +$521,000 +8.2% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q3 2016 $29,441,000 $9,573,000 +$3,890,000 +68% 01 Jul 2016 30 Sep 2016 10-Q 01 Nov 2017 2017 Q3
Q2 2016 $25,551,000 $6,830,000 +$900,000 +15% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $24,651,000 $6,690,000 -$7,466,000 -53% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q4 2015 $32,117,000 $6,348,000 +$581,000 +10% 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
Q3 2015 $31,536,000 $5,683,000 +$1,034,000 +22% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $30,502,000 $5,930,000 +$343,000 +6.1% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $30,159,000 $14,156,000 +$9,814,000 +226% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $20,345,000 $5,767,000 +$2,116,000 +58% 01 Oct 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
Q3 2014 $18,229,000 $4,649,000 +$1,162,000 +33% 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2014 $17,067,000 $5,587,000 +$3,269,000 +141% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015 2015 Q2
Q1 2014 $13,798,000 $4,342,000 +$2,671,000 +160% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1
Q4 2013 $11,127,000 $3,651,000 +$2,413,000 +195% 01 Oct 2013 31 Dec 2013 10-K 25 Feb 2016 2015 FY
Q3 2013 $8,714,000 $3,487,000 +$2,795,000 +404% 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2013 2013 Q3
Q2 2013 $5,919,000 $2,318,000 +$1,878,000 +427% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $4,041,000 $1,671,000 +$963,000 +136% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q4 2012 $3,078,000 $1,238,000 01 Oct 2012 31 Dec 2012 10-K 26 Feb 2015 2014 FY
Q3 2012 $692,000 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $440,000 -$152,000 -26% 01 Apr 2012 30 Jun 2012 10-Q 08 Aug 2013 2013 Q2
Q1 2012 $708,000 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1
Q2 2011 $592,000 01 Apr 2011 30 Jun 2011 10-Q 07 Nov 2012 2012 Q3

Sarepta Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $182,514,000 -$50,504,000 -22% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 $233,018,000 +$119,075,000 +105% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $113,943,000 +$5,873,000 +5.4% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $108,070,000 +$29,468,000 +37% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $78,602,000 +$28,475,000 +57% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $50,127,000 +$19,662,000 +65% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $30,465,000 +$503,000 +1.7% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $29,962,000 -$2,155,000 -6.7% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $32,117,000 +$11,772,000 +58% 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
2014 $20,345,000 +$9,218,000 +83% 01 Jan 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
2013 $11,127,000 +$8,049,000 +262% 01 Jan 2013 31 Dec 2013 10-K 25 Feb 2016 2015 FY
2012 $3,078,000 -$51,000 -1.6% 01 Jan 2012 31 Dec 2012 10-K 26 Feb 2015 2014 FY
2011 $3,129,000 -$40,000 -1.3% 01 Jan 2011 31 Dec 2011 10-K 03 Mar 2014 2013 FY
2010 $3,169,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.